Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CARsgen Granted US Orphan Drug Status for Claudin18.2 CAR-T Drug

publication date: Oct 5, 2020

Shanghai's CARsgen Therapeutics was granted orphan drug designation in the US for its anti-claudin18.2 autologous CAR-T candidate in patients with gastric and gastroesophageal junction adenocarcinoma. Previously, CARsgen was awarded orphan drug status in China. CT041 is the first claudin18.2-targeted CAR T-cell approved to start trials in the US and the first in China as well. A Phase Ib trial of the candidatel is underway for patients with advanced gastric, gastroesophageal or pancreatic adenocarcinoma. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021